Correlation Between PennyMac Finl and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both PennyMac Finl and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PennyMac Finl and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PennyMac Finl Svcs and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on PennyMac Finl and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PennyMac Finl with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of PennyMac Finl and Acrivon Therapeutics,.

Diversification Opportunities for PennyMac Finl and Acrivon Therapeutics,

-0.05

Correlation Coefficient

PennyMac Finl  Acrivon Therapeutics,

Good diversification

The 3 months correlation between PennyMac and Acrivon is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding PennyMac Finl Svcs and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and PennyMac Finl is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PennyMac Finl Svcs are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of PennyMac Finl i.e., PennyMac Finl and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between PennyMac Finl and Acrivon Therapeutics,

Given the investment horizon of 90 days PennyMac Finl Svcs is expected to generate 0.26 times more return on investment than Acrivon Therapeutics,. However, PennyMac Finl Svcs is 3.8 times less risky than Acrivon Therapeutics,. It trades about -0.2 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.17 per unit of risk. If you would invest  10,615  in PennyMac Finl Svcs on October 4, 2024 and sell it today you would lose (631.00) from holding PennyMac Finl Svcs or give up 5.94% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

PennyMac Finl Svcs  vs.  Acrivon Therapeutics, Common

PennyMac Finl Svcs

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PennyMac Finl Svcs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, PennyMac Finl is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with PennyMac Finl and Acrivon Therapeutics,

The main advantage of trading using opposite PennyMac Finl and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PennyMac Finl position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind PennyMac Finl Svcs and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.